Hierarchical endpoints and win statistics for geromedicine trials.

Authors

Mahmoud Abdellatif, Yevgeniy Kim, Guido Kroemer

Published in

Nature aging. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Geroscience has advanced rapidly, yet its clinical translation remains limited. A central barrier is the lack of trial outcomes that capture the multidimensional effects of geroprotective interventions while meeting clinical and regulatory standards. Mortality is objective and regulatorily salient but often impractical. By contrast, surrogate measures of healthspan improve feasibility and may better reflect the quality of extended life, but they are generally considered soft endpoints that require further validation. Here, we propose hierarchical composite endpoints using time-to-worst-event analysis as a pragmatic and scientifically sound compromise. Participant pairs are compared using win statistics according to a prespecified clinical hierarchy, in which more severe and objective clinical events are prioritized, while health surrogates and biomarkers contribute information at lower tiers. When outcome selection, ordering and tie rules are clinically and mechanistically justified and agreed with regulators, this approach may improve geromedicine trial efficiency and allow overall treatment effects to be captured without compromising clinical priorities.

PMID:
42342910
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.